YI — 111, Inc.

Summary of YI (Q4 2024) Earnings Call

1. Key Financial Results and Metrics

• Q4 2024 Performance:

  • Total net revenues: RMB 3.8 billion, down 6.3% year-over-year.
  • Gross segment profit: RMB 202.5 million, a decrease of 5.5%.
  • Total operating expenses: RMB 209.8 million, reduced by 50.1%, representing 5.5% of revenues (down from 10.2%).
  • Non-GAAP loss from operations: RMB 2.3 million, an improvement of 95.8% from RMB 55.2 million a year earlier.
  • Non-GAAP net loss attributable to ordinary shareholders: RMB 14.8 million, improved by 74.9%.

• Full Year 2024 Performance:

  • Net revenues: RMB 14.4 billion, a decrease of 3.7%.
  • Gross segment profit: RMB 829.2 million, down 2.3%.
  • Income from operations: RMB 2.1 million, a turnaround from a loss of RMB 351 million in 2023.
  • Positive operating cash flow: RMB 263 million for the first time.

2. Strategic Updates and Business Highlights

• Achieved first-ever operational profitability and positive cash flow, marking a significant milestone.
• Reduced total operating expenses by 31% year-over-year, with a focus on operational efficiency.
• Enhanced digital capabilities and supply chain infrastructure, including the expansion of fulfillment centers to 18.
• Launched the Kunpeng Network to streamline logistics and improve delivery efficiency.
• Continued investment in AI and technology to optimize operations and enhance customer engagement.
• Recognized as a leading healthcare and pharmaceutical company for investment potential.

3. Forward Guidance and Outlook

• Management remains optimistic about 2025, focusing on leveraging AI and digital transformation to drive efficiency and profitability.
• Plans to expand partnerships with pharmaceutical companies and pharmacies to enhance product offerings and market reach.
• Anticipates ongoing regulatory changes in the healthcare sector that may impact operations but believes it can leverage its technological advantages.

4. Bad News, Challenges, or Points of Concern

• The macroeconomic environment in China has led to cautious consumer behavior and declining retail sales growth, impacting the healthcare sector.
• Total retail pharmacy sales dropped by 2.2% in 2024, reflecting increased competition and market saturation.
• Despite operational improvements, revenue and gross profit decreased, indicating challenges in maintaining growth amid a tough market.
• Concerns regarding the sustainability of profitability in a fluctuating market environment, especially with ongoing healthcare reforms.

5. Notable Q&A Insights

• Management emphasized the importance of operational efficiency and AI in achieving profitability, with a focus on optimizing costs without sacrificing revenue.
• Discussion on the impact of the macroeconomic environment highlighted the company's resilience and strategic adjustments to navigate challenges.
• Plans for further expense control in 2025 were confirmed, with ongoing optimization ingrained in the company culture.
• Management expressed confidence in the long-term potential of the healthcare market in China, driven by aging demographics and ongoing reforms aimed at improving efficiency.

This summary encapsulates the key points from the earnings call, providing a balanced view of YI's financial performance, strategic initiatives, and challenges faced in the current market landscape.